Stock Ratings / Health Care / AMLX / financials

ACAD (66) OGN (61) XENE (37) IRON (54) ⌘ Pro Terminal →

Amylyx Pharmaceuticals Inc. (AMLX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$28.68 +2.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Amylyx Pharmaceuticals Inc. (AMLX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.60B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMLX)Realized 20D OHLCV Swing Band: ±10.1%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AMLX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $380.8M

FY24

Rev $87.4M

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-3.8%	-$144.7M	-$123.5M	-45%
FY 2024	$87.4M	93.2%	-80%	-$301.7M	-$167.8M	-45%
FY 2023	$380.8M	52%	10.2%	$49.3M	$11.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMLX)

✓Walkthrough of AMLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +79.25%🛡️ HOLDING TREND SUPPORT

2026-10-30O $28.41H $29.09L $28.00C $28.68VOL 989.5K

RES: $36.51SUP: $27.21SMA50: $30.89SMA200: $20.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMLX Butterfly Map → + Track AMLX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMLX)

Health Care Rank #694 of 1016 ⚔️ ACAD vs AMLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMLX vs. ACAD, OGN, XENE, IRON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amylyx Pharmaceuticals Inc. (AMLX) ranks #694 by composite RQD confidence (38/100, grade D-) and #192 by equity capitalization ($3.60B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. ACAD currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with AMLX at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMLX ACTIVE Amylyx Pharmaceuticals Inc.	D-	38/100	—	—	-35.0%	+2.17%	$3.60B	Benchmark Subject
ACAD ACADIA Pharmaceuticals Inc.	C+	66/100	9.1x	91.7%	7.9%	+2.17%	$3.58B	/acad-vs-amlx →
OGN Organon & Co.	C-	61/100	19.4x	53.3%	24.9%	+0.22%	$3.63B	/ogn-vs-amlx →
XENE Xenon Pharmaceuticals Inc.	D-	37/100	—	—	-35.0%	+3.30%	$3.64B	/xene-vs-amlx →
IRON Disc Medicine Inc.	D+	54/100	—	—	-27.5%	-0.43%	$3.68B	/iron-vs-amlx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001658551

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amylyx Pharmaceuticals Inc. (AMLX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $87.4M , and -100.0% cumulative change since FY2023) , GAAP net income of -$144.7M, operating cash flow of -$123.3M, and free cash flow of -$123.5M (+26.4% YoY). On the balance sheet, AMLX closed FY2025 with $332.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$144.7M	-$123.3M	-$123.5M	$332.6M	—
FY2024 (FY)	2024-12-31	$87.4M	-$301.7M	-$167.6M	-$167.8M	$193.6M	—
FY2023 (FY)	2023-12-31	$380.8M	$49.3M	$11.9M	$11.9M	—	—

3. AMLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $28.68 (+2.17% 1D, market cap $3.60B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AMLX ranks #694 in composite RQD confidence.

How does AMLX compare to ACAD and OGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACAD (ACADIA Pharmaceuticals Inc.) holds a C+ grade (66/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.58B) and OGN (Organon & Co.) posts a C- grade (61/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMLX?

Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMLX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMLX last traded at $28.68 (+2.17% on volume of 905,509 shares), positioning the stock -7.15% below its 50-day simple moving average ($30.89) and +42.83% above its 200-day simple moving average ($20.08). Across its 52-week range of $10.83 to $41.14, AMLX sits at the 58.9% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($25.78 to $31.58).